These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26218744)

  • 1. Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.
    Xiao K; Li YP; Wang C; Ahmad S; Vu M; Kuma K; Cheng YQ; Lam KS
    Biomaterials; 2015 Oct; 67():183-93. PubMed ID: 26218744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy.
    Chen G; Jaskula-Sztul R; Harrison A; Dammalapati A; Xu W; Cheng Y; Chen H; Gong S
    Biomaterials; 2016 Aug; 97():22-33. PubMed ID: 27156249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery.
    Li Y; Xiao K; Luo J; Xiao W; Lee JS; Gonik AM; Kato J; Dong TA; Lam KS
    Biomaterials; 2011 Sep; 32(27):6633-45. PubMed ID: 21658763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy.
    Jaskula-Sztul R; Xu W; Chen G; Harrison A; Dammalapati A; Nair R; Cheng Y; Gong S; Chen H
    Biomaterials; 2016 Jun; 91():1-10. PubMed ID: 26994874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
    Weinlander E; Somnay Y; Harrison AD; Wang C; Cheng YQ; Jaskula-Sztul R; Yu XM; Chen H
    J Surg Res; 2014 Jul; 190(1):191-7. PubMed ID: 24679699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.
    Wang XS; Kong DJ; Lin TY; Li XC; Izumiya Y; Ding XZ; Zhang L; Hu XC; Yang JQ; Gao SG; Lam KS; Li YP
    Acta Pharmacol Sin; 2017 Jun; 38(6):931-942. PubMed ID: 28552907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facile construction of bioreducible crosslinked polypeptide micelles for enhanced cancer combination therapy.
    Ruttala HB; Chitrapriya N; Kaliraj K; Ramasamy T; Shin WH; Jeong JH; Kim JR; Ku SK; Choi HG; Yong CS; Kim JO
    Acta Biomater; 2017 Nov; 63():135-149. PubMed ID: 28890258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
    Li LH; Zhang PR; Cai PY; Li ZC
    Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
    Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
    Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
    Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma.
    Xiao K; Liu Q; Al Awwad N; Zhang H; Lai L; Luo Y; Lee JS; Li Y; Lam KS
    Nanoscale; 2018 May; 10(17):8207-8216. PubMed ID: 29682647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
    Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
    Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
    Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
    Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links.
    Koo AN; Min KH; Lee HJ; Lee SU; Kim K; Kwon IC; Cho SH; Jeong SY; Lee SC
    Biomaterials; 2012 Feb; 33(5):1489-99. PubMed ID: 22130564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ diselenide-crosslinked polymeric micelles for ROS-mediated anticancer drug delivery.
    Deepagan VG; Kwon S; You DG; Nguyen VQ; Um W; Ko H; Lee H; Jo DG; Kang YM; Park JH
    Biomaterials; 2016 Oct; 103():56-66. PubMed ID: 27372421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.